LuminaCare Solutions provides a SaaS based Therapeutics platform
Tools to personalize treatments for patients to give the right drug,
at the right dose and right time.
Antibiotic resistance is a worldwide problem . New forms of antibiotic resistance can cross international boundaries and spread between continents with ease . World health leaders have described antibiotic-resistant microorganisms as “nightmare bacteria” that “pose a catastrophic threat” to people worldwide .
The CDC estimates that each year, atleast 2 million people in the US alone are infected with drug-resistant bacteria and atleast 23,000 people die as a direct result. The CDC has awarded more than $200 million through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) cooperative agreement to help states, cities, counties, and territories prevent, detect, respond to, and control the growing threats posed by emerging and re-emerging infectious diseases.
The FDA responded with updated guidance, highlighting the use of adaptive clinical trials in development of new antibiotics. The GAIN Act further incentivizes antibacterial drug development by prioritizing review and enabling fast-track approval by the FDA.
Untreatable and hard-to-treat infections from carbapenem-resistant Enterobacteriaceae (CRE) bacteria are on the rise among patients in medical facilities. CRE have become resistant to nearly all existing antibiotics . Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection.
Clostridium difficile (C. difficile) causes life-threatening diarrhea. These infections mostly occur in people who have had both recent medical care and antibiotics. Often, C. difficile infections occur in hospitalized or recently hospitalized patients.
Methicillin-resistant Staphylococcus aureus (MRSA) causes a range of illnesses, from skin and wound infections to pneumonia and bloodstream infections that can cause sepsis and death. Staph bacteria, including MRSA, are one of the most common causes of healthcare-associated infections.
Pseudomonas aeruginosa is a common cause of healthcare-associated infections including pneumonia, bloodstream infections, urinary tract infections, and surgical site infections.
Streptococcus pneumoniae ( or pneumococcus) is the leading cause of bacterial pneumonia and meningitis in the US. It is also a major cause of bloodstream infections and ear and sinus infections.
MDR Bacterial Infections Cost the Healthcare System
Patients with multi-drug resistant (MDR) bacterial infections have higher mortality rates (almost twice) as compared to patients with susceptible infections. The average length of hospital stay is longer by 6.4 to 12.7 days for patients with MDR bacterial infection. The longer hospital stays effect an increase in costs by about $18000 – $80,000. 35% of patients infected by MDR bacteria in the hospital are readmitted within one year with a median time of 27 days.
Appropriate treatment within 24 hours of diagnosis can
- reduce mortality rate and improve patient outcome
- reduce re-admission rates
- reduce hospitalization costs
CMS Driving Change
Centers of Medicare & Medicaid Services (CMS) is now penalizing hospitals for some hospital-acquired infections (HAIs) and readmissions for pneumonia and COPD. In 2017, CMS penalties for 2600 hospitals will be about $528 million for readmission. Approximately 60% HAI patients are insured through CMS.
Lost Hospital Income from Resistant Bacterial Infections
Hospital Acquired Infections (HAI) account for $56B of lost income annually for hospitals.
- Unreimbursed cost – $10B
- Opportunity cost – $46B
Approximately 70% of HAIs are caused by drug-resistant bacteria, leading to longer lengths of hospital stay for treatment.